- Home
- CRVS vs DSM Comparison
CRVS vs DSM Comparison
Compare CRVS & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- DSM
- Stock Information
- Founded
- CRVS 2014
- DSM 1989
- Country
- CRVS United States
- DSM United States
- Employees
- CRVS N/A
- DSM N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- DSM Investment Managers
- Sector
- CRVS Health Care
- DSM Finance
- Exchange
- CRVS Nasdaq
- DSM Nasdaq
- Market Cap
- CRVS 257.0M
- DSM 289.7M
- IPO Year
- CRVS 2016
- DSM N/A
- Fundamental
- Price
- CRVS $3.21
- DSM $5.86
- Analyst Decision
- CRVS Strong Buy
- DSM
- Analyst Count
- CRVS 5
- DSM 0
- Target Price
- CRVS $12.63
- DSM N/A
- AVG Volume (30 Days)
- CRVS 704.3K
- DSM 161.7K
- Earning Date
- CRVS 05-05-2025
- DSM 01-01-0001
- Dividend Yield
- CRVS N/A
- DSM 3.97%
- EPS Growth
- CRVS N/A
- DSM N/A
- EPS
- CRVS N/A
- DSM N/A
- Revenue
- CRVS N/A
- DSM N/A
- Revenue This Year
- CRVS N/A
- DSM N/A
- Revenue Next Year
- CRVS N/A
- DSM N/A
- P/E Ratio
- CRVS N/A
- DSM N/A
- Revenue Growth
- CRVS N/A
- DSM N/A
- 52 Week Low
- CRVS $1.30
- DSM $4.69
- 52 Week High
- CRVS $10.00
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- CRVS 29.29
- DSM 49.20
- Support Level
- CRVS $3.06
- DSM $5.75
- Resistance Level
- CRVS $3.45
- DSM $6.10
- Average True Range (ATR)
- CRVS 0.37
- DSM 0.05
- MACD
- CRVS -0.10
- DSM -0.00
- Stochastic Oscillator
- CRVS 8.77
- DSM 61.11
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.